XBI is trading 3.5% down at $146.14 amid a sharp biotech pullback and a sector-wide risk-off shift.
- The biotechnology group is down over 3% without a single clear catalyst, though negative stock-specific news like Karyopharm’s failed clinical trial has weighed on sentiment.
- Given the lack of major ETF-specific headlines, today’s move appears driven by broader market dynamics rather than news specific to the fund.